> Detailanzeige

Görtz, Magdalena [VerfasserIn]; Huber, Ann-Kathrin [VerfasserIn]; Linz, Tim [VerfasserIn]; Schwab, Constantin [VerfasserIn]; Stenzinger, Albrecht [VerfasserIn]; Goertz, Lukas [VerfasserIn]; Bonekamp, David [VerfasserIn]; Schlemmer, Heinz-Peter [VerfasserIn]; Hohenfellner, Markus [VerfasserIn]

Detection rate of prostate cancer in repeat biopsy after an initial negative magnetic resonance imaging/ultrasound-guided biopsy

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Detection rate of prostate cancer in repeat biopsy after an initial negative magnetic resonance imaging/ultrasound-guided biopsy
  • Beteiligte: Görtz, Magdalena [VerfasserIn]; Huber, Ann-Kathrin [VerfasserIn]; Linz, Tim [VerfasserIn]; Schwab, Constantin [VerfasserIn]; Stenzinger, Albrecht [VerfasserIn]; Goertz, Lukas [VerfasserIn]; Bonekamp, David [VerfasserIn]; Schlemmer, Heinz-Peter [VerfasserIn]; Hohenfellner, Markus [VerfasserIn]
  • Erschienen: 17 May 2023
  • Erschienen in: Diagnostics ; 13(2023), 10, Artikel-ID 1761, Seite 1-16
  • Sprache: Englisch
  • DOI: 10.3390/diagnostics13101761
  • ISSN: 2075-4418
  • Identifikator:
  • Schlagwörter: magnetic resonance imaging ; MRI/TRUS fusion biopsy ; PI-RADS ; prostate cancer ; prostate-specific antigen
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: A negative multiparametric magnetic resonance imaging (mpMRI)-guided prostate biopsy in patients with suspected prostate cancer (PC) results in clinical uncertainty, as the biopsy can be false negative. The clinical challenge is to determine the optimal follow-up and to select patients who will benefit from repeat biopsy. In this study, we evaluated the rate of significant PC (sPC, Gleason score ≥7) and PC detection in patients who received a follow-up mpMRI/ultrasound-guided biopsy for persistent PC suspicion after a negative mpMRI/ultrasound-guided biopsy. We identified 58 patients at our institution that underwent repeat targeted biopsy in case of PI-RADS lesions and systematic saturation biopsy between 2014 and 2022. At the initial biopsy, the median age was 59 years, and the median prostate specific antigen level was 6.7 ng/mL. Repeat biopsy after a median of 18 months detected sPC in 3/58 (5%) patients and Gleason score 6 PC in 11/58 (19%). Among 19 patients with a downgraded PI-RADS score at the follow-up mpMRI, none had sPC. In conclusion, men with an initial negative mpMRI/ultrasound-guided biopsy had a high likelihood of not harboring sPC at repeat biopsy (95%). Due to the small size of the study, further research is recommended.
  • Zugangsstatus: Freier Zugang